Speaking to The Guardian, former director of the US Food and Drug Administration's office of orphan products development, Tim Cote said that the approval of Glybera could prove to be a major milestone in gene therapy treatments.
"This is a watershed moment. Gene therapy holds incredible promise for people, especially those with rare diseases. This is not an isolated example, this is the beginning of something. It paves the way for the approval of other treatments of this kind", he said.
Source: Medindia